In the tumor samples, CD4+ T cells were already more prevalent than CD8+ T cells (34% vs. 19.5%), and in pre-REP TILs and REP TILs, the CD4+ T cell dominance further increased (46.8% and 68.4%, respectively; Fig. 1A). The gene discussed is CD8A; the disease is neoplasm.